Health  Vol.8 No.12 , September 2016
HCV and HIV Infection among Heroin Abusers in a Methadone Maintenance Treatment Program
Abstract: Over the years, it was getting attention to hepatitis C virus (HCV) and human immu-nodeficiency virus (HIV) infection among injected drug users (IDUs) in Taiwan. This study investigated the frequency of risky behaviors for HCV carriers and IDUs who were HIV carriers in methadone maintenance treatment program. The subjects, intravenously injected heroin abusers, were collected from a special methadone maintenance treatment clinic. The survey included characteristics of participants, sexual activity and attitude towards condom usage. The total number of subjects was 151. Data were analyzed using the statistical package SPSS 15.0. The analytical methods included descriptive analysis, Fisher’s exact test, and the logistic regression model. The study showed that 82% of intravenously injected heroin abusers were hepatitis C virus (HCV)-positive, and 44.4% were hepatitis B virus (HBV)-positive; 89.5% of HIV-positive heroin abusers were type C hepatitis positive. Only 21.2% of these intra-venously injected heroin abusers always used a condom, and 39.7% never used a condom during sexual activity. Logistic regression analysis showed smoking, sharing syringes needles, HBV status and condom use status were four main risk factors on HIV infection. Sharing or using contaminated syringes needles was the main cause of HIV, HBV, and HCV infection in the drug addiction group. Since our government has the policy of providing a methadone maintenance treatment program, the spread of HIV is under control, but knowledge about HIV and safe sex education still needs improvement.
Cite this paper: Lee, Y. , Chao, J. , Shi, M. , Ma, M. , Chao, I. (2016) HCV and HIV Infection among Heroin Abusers in a Methadone Maintenance Treatment Program. Health, 8, 1209-1222. doi: 10.4236/health.2016.812124.

[1]   Taiwan Center for Disease Control. HIV/AIDS.

[2]   Fischer, B., Rehm, J., Brissette, S., Brochu, S., Bruneau, J., el-Guebaly, N., et al. (2005) Illicit Opioid Use in Canada: Comparing Social, Health, and Drug Use Characteristics of Untreated Users in Five Cities (OPICAN Study). Journal of Urban Health, 82, 250-266.

[3]   Ross, J., Teesson, M., Darke, S., Lynskey, M., Ali, R., Ritter, A., et al. (2005) The Characteristics of Heroin Users Entering Treatment: Findings from the Australian Treatment Outcome Study (ATOS). Drug and Alcohol Review, 24, 411-418.

[4]   Bargagli, A. M., Hickman, M., Davoli, M., Perucci, C.A., Schifano, P., Buster, M., Brugal, T. and Vicente, J. (2006) Drug-Related Mortality and Its Impact on Adult Mortality in Eight European Countries. European Journal of Public Health, 16, 198-202.

[5]   Yen, Y.F., Rodwell, T.C., Yen, M.Y., Hsu, Y.H., Chuang, P., Li, L.H., et al. (2012) HIV Infection Risk among Injection Drug Users in a Methadone Maintenance Treatment Program, Taipei, Taiwan 2007-2010. American Journal of Drug and Alcohol Abuse, 38, 544- 550.

[6]   Lee, K.C.K., Lim, W.W.L. and Lee, S.S. (2008) High Prevalence of HCV in a Cohort of Injectors on Methadone Substitution Treatment. Journal of Virology, 41, 297-300.

[7]   Zhang, C., Yang, R., Xia, X., Cheng H., Choi KH., Zheng X., et al. (2002) High Prevalence of HIV-1 and Hepatitis C Virus Coinfection among Injection Drug Users in the Southeastern Region of Yunnan, China. Journal of Acquired Immune Deficiency Syndromes, 9, 191-196.

[8]   Xia, X., Luo, J., Bai, J., Jia, Y., Lu, F., Zeng, G., et al. (2008) Epidemiology of Hepatitis C virus Infection among Injection Drug Users in China: Systematic Review and Meta-Analysis. Public Health, 122, 990-1003.

[9]   Burt, R.D., Hagan, H., Garfein, R.S., Sabin, K., Weinbaum, C., Thiede, H., et al. (2007) Trends in Hepatitis b Virus, Hepatitis c Virus, and Human Immunodeficiency Virus Prevalence, Risk Behaviors, and Preventive Measures among Seattle Injection Drug Users Aged 18-30 Years, 1994-2004. Journal of Urban Health, 84, 436-454.

[10]   Segurado, A.C., Braga, P., Etzel, A., Yoshida, C.F., Rolla, V.C., Mendes, J.M., et al. (2004) Hepatitis C Virus Coinfection in a Cohort of HIV-Infected Individual from Santos, Brazil: Seroprevalence and Associated Factors. AIDS Patient Care STD, 18,135-143.

[11]   Solomon, S.S., Desai, M., Srikrishnan, A.K., Thamburaj, E., Vasudevan, C.K., Kumar, M.S., et al. (2010) The Profile of Injection Drug Users in Chennai, India: Identification of Risk Behaviours and Implications for Interventions. Substance Use and Misuse, 45, 354-367.

[12]   Yang, C.H., Chio, M.Y., Huang, Y.F., Chen, T.L., Chen, H.P., Fung, C.P., et al. (2008) Compendium Report—Guidelines for Diagnosis and Treatment of HIV/AIDS. Taiwan Epidemiology Bulletin, 24, 837-844.

[13]   Cleland, C.M., Des Jarlais, D.C., Theresa, E., Pouget, E.R., Hagan, H., Coffin, L.S., et al. (2007) HIV Risk Behaviors among Female IDUs in Developing and Transitional Countries. The WHO Phase II Drug Injection Collaborative Study Group. BMC Public Health, 7, 271.

[14]   Aceijas, C., Stimson, G.V., Hickman, M., Friedman, S.R., Cooper, H.L., Wiessing, L., et al. (2004) Global Overview of Injecting Drug Use and HIV Infection among Injecting Drug Users. Journal of Acquired Immune Deficiency Syndromes, 18, 2295-2303.

[15]   Bluthenthal, R.N., Do, D.P., Finch, B., Martinez, A., Edlin, B.R., Kral, A.H., et al. (2007) Community Characteristics Associated with HIV Risk among Injection Drug Users in the San Francisco Bay Area: A Multilevel Analysis. Journal of Urban Health, 84, 653-666.

[16]   Sees, K.L., Delucchi, K.L., Masson, C., et al. (2000) Methadone Maintenance vs. 180-Day Psychosocially Enriched Detoxification for Treatment of Opioid Dependence: A Randomized Controlled Trial. JAMA, 283, 1303-1310.

[17]   Hou, J.Y., Sun, T.C., Huang, C.H., Chen, M.R., Kao, H.A., Hsiao, J.Y., et al. (2009) The Clinical Implications of Methadone Maintenance Treatment for Heroin Addicts in Jail—A Preliminary Report. TSMH Medical & Nursing Journal, 15, 111-124. (Chinese Version)

[18]   Chen, Y.M. (2005) Molecular Epidemiology of HIV-1 Infection among Injecting Drug Users in Taiwan. 2005 Taipei International Conference on Drug Control and Addition Treatment, Taipei, 22-24 November 2005, 22-24.

[19]   Bruce, R.D. (2010) Methadone as HIV Prevention: High Volume Methadone Sites to Decrease HIV Incidence Rates in Resource Limited Settings. International Journal of Drug Policy, 21, 122-124.

[20]   Corsi, K.F., Lehman, W.K. and Booth, R.E. (2009) The Effect of Methadone Maintenance on Positive Outcomes for Opiate Injection Drug Users. Journal of Substance Abuse Treatment, 37, 120-126.

[21]   Gowing, L.R., Farrell, M., Bornemann, R., Babor, T.F., Farrell, M., Formigoni, M.L., et al. (2006) Methadone Treatment of Injecting Opioid Users for Prevention of HIV Infection. Journal of General Internal Medicine, 21, 193-195.

[22]   Sorensen, J.L. and Copeland, A.L. (2000) Drug Abuse Treatment as an HIV Prevention Strategy: A Review. Drug and Alcohol Dependence, 59, 17-31.

[23]   Aceijas, C., Friedman, S.R., Cooper, H.L., Wiessing, L., Stimson, G.V., Hickman, M., et al. (2006) Estimates of Injecting Drug Users at the National and Local Level in Developing and Transitional Countries, and Gender and Age Distribution. Sexually Transmitted Infections, 82, 10-17.

[24]   NACO (2006) HIV Sentinel Surveillance 2006 India Country Report.

[25]   Brogly, S.B., Bruneau, J., Vincelette, J., Lamothe, F., Franco, E.L., Hul-chanski, J.D., et al. (2000) Risk Behavior Change and HIV Infection among Injection Drug Users in Montreal. Journal of Acquired Immune Deficiency Syndromes, 14, 2575-2582.

[26]   Riehman, K.S., Kral, A.H., Anderson, R., Sullivan, L.E., Moore, B.A., Chawarski, M.C., et al. (2004) Sexual Relationship, Secondary Syringe Exchange, and Gender Difference in HIV Risk among Drug Injectors. Journal of Urban Health, 81, 249-259.

[27]   Spittal, P.M., Craib, K., Wood, E., Laliberte, N., Hogg, R.S., Li, K., et al. (2002) Risk Factors for Elevated HIV Incidence Rates among Female Injection Drug Users in Vancouver. Canadian Medical Association Journal, 166, 894-899.

[28]   Purcell, D.W., Metsch, L.R., Latka, M., Santibanez, S., Gomez, C.A., Eldred, L., et al. (2004) Interventions for Seropositive Injectors-Research and Evaluation: An Integrated Behavioral Intervention with HIV-Positive Injection Drug Users to Address Medical Care, Adherence, and Risk Reduction. Journal of Acquired Immune Deficiency Syndromes, 37, S110-S118.

[29]   Avants, S.K., Warburton, L.A., Hawkins, K.A. and Margolin, A. (2000) Continuation of High-Risk Behavior by HIV-Positive Drug Users. Treatment Implications. Journal of Substance Abuse Treatment, 19, 15-22.

[30]   Miguez-Burbano, M.J., Pineda-Medina, L., Lecusay, R. and Page, J.B. (2002) Continued High Risk Behaviors in HIV Infected Drug Abusers. Journal of Addictive Diseases, 21, 67- 80.

[31]   Latkin, C.A., Forman-Hoffman, V.L., D’Souza, G., Knowlton, A.R., Neblett, R.C., Davey-Rothwell, M., et al. (2004) Associations between Medical Service Use and HIV Risk among HIV Positive Drug Users in Baltimore, MD. AIDS Care, 16, 901-908.

[32]   Garten, R.J., Zhang, J., Lai, S., Liu, W., Chen, J., Yu, X.F., et al. (2005) Coin-fection with HIV and Hepatitis C Virus among Injection Drug Users in Southern China. Clinical Infectious Diseases, 41, S18-S24.

[33]   Solomon, S.S., Srikrishnan, A.K., Mehta, S.H., Vasudevan, C.K., Murugavel, K., Thamburaj, E., et al. (2008) High Prevalence of HIV, HIV/Hepatitis C Virus Co-Infection and Risk Behaviors among IDUs in Chennai, India: A Cause for Concern. Journal of Acquired Immune Deficiency Syndromes, 49, 327-332.

[34]   Kheirandish, P., SeyedAlinaghi, S., Jahani, M., Shirzad, H., Ahmadian, M.S., Majidi, A., et al. (2009) Prevalence and Correlates of Hepatitis C Infection among Male Injection Drug Users in Detention, Tehran, Iran. Journal of Urban Health, 86, 902-908.

[35]   Lee, H.Y., Li, J.H., Wu, L.T., Wu, J.S., Yen, C.F. and Tang, H.P. (2012) Survey of Methadone-Drug Interactions among Patients of Methadone Maintenance Treatment Program in Taiwan. Substance Abuse Treatment, Prevention, and Policy, 7, 11.

[36]   Fattovich, G., Stroffolini, T., Zangni, I. and Donato, F. (2004) Hepatocellular Carcinoma in Cirrhosis: Incidence and Risk Factors. Gastroenterology, 127, S35-S50.

[37]   Lee, H.Y., Yang, Y.H., Yu, W.J. and Li, J.H. (2012) Essentiality of HIV Testing and Education for Effective HIV Control in the National Pilot Harm Reduction Program: The Taiwan Experience. Kaohsiung Journal of Medical Sciences, 28, 79-85.

[38]   Willner-Reed, J., Belendiuk, K.A., Epstein, D.H., Schmittne, J. and Preston, K.L. (2008) Hepatitis C and HIV Risk Behaviors in Poly Drug Users on Methadone Maintenance. Journal of Substance Abuse Treatment, 35, 78-86.